GlassScriptPhysician profile
Drew Venables
NPI 1053795997
$12,469.15
in general payments reported to CMS, 2019-2025
30 companies · $3,226 in 2025
The $3,226 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,427 · 2022: $1,619 · 2023: $2,724 · 2024: $3,474 · 2025: $3,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,134 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,134.41 |
| Education | $289.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,742.24 | 2021-2025 | |
| Janssen Biotech, INC. | $1,728.78 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $1,180.75 | 2021-2025 | |
| Lilly USA, LLC | $1,160.63 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $1,075.47 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $804.29 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $687.77 | 2022-2025 | Adbry, Anzupgo |
| Incyte Corporation | $630.30 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $613.34 | 2021-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $586.89 | 2023-2024 | Vtama |
| Ucb, INC. | $513.71 | 2021-2025 | Bimzelx |
| Pfizer INC. | $490.82 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $353.47 | 2021-2025 | Ilumya, Blu-U, Odomzo |
| Amgen INC. | $131.77 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $97.25 | 2022-2025 | Nemluvio, Epsolay, Twyneo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $90.58 | 2024-2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $90.26 | 2023-2024 | Zoryve |
| Sanofi-Aventis U.S. LLC | $89.95 | 2024 | |
| Biofrontera INC. | $67.40 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.33 | 2022-2025 | Spevigo |
| Genentech USA, INC. | $47.29 | 2023 | Xolair, Erivedge |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.04 | 2021-2024 | Jublia, Cabtreo, Arazlo |
| Journey Medical Corporation | $31.63 | 2022-2023 | |
| Kerecis Limited | $29.04 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Fresenius Kabi USA, LLC | $26.33 | 2023 | Idacio |
| Abbott Laboratories | $24.53 | 2022 | |
| Almirall LLC | $21.78 | 2025 | Klisyri |
| Vyne Pharmaceuticals INC. | $21.54 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $18.75 | 2022 | |
| Dermira, INC. | $18.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Venables listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.